FDA Brief

Warning letters Drugs

FDA warning letter to

Prodose, Inc. formerly known as Spirit Pharmaceuticals LLC

LowIssued Mar 28, 2025Posted Apr 29, 2025Center for Drug Evaluation and Research (CDER)

Prodose, formerly Spirit Pharmaceuticals, left a cold and flu drug mislisted; FDA calls it misbranded.

What happened

FDA reviewed the firm's drug listing in its electronic Drug Registration and Listing System (eDRLS) for Maximum Strength Nighttime Sever Cold and Flu, NDC 68210-4210, after earlier letters to Spirit Pharmaceuticals on March 30, 2023 and December 30, 2024, and a data removal notice on February 13, 2025. The review found the strength of the active ingredient doxylamine succinate did not match between the labeling (6.25 mg) and the structured product labeling part of the listing, and that the listed name spelled "severe" as "sever" while the label reads "Severe." FDA said no response was received and the product's data was removed from the National Drug Code Directory.

What FDA found

  1. The listing did not correctly give the name and quantity of the active ingredient: the label says doxylamine succinate 6.25 mg, but the listing's strength field says something else.

    21 CFR 207.49(a)(4)
  2. The name in the listing does not match the label, which reads "Severe" while the listing says "Sever."

    section 510(j) of the FD&C Act, 21 U.S.C. 360(j)
  3. Because the listing is wrong, FDA considers the drug misbranded (its required labeling information is not correct).

    section 502(o) of the FD&C Act, 21 U.S.C. 352(o)
  4. Sending a misbranded drug into interstate commerce is prohibited.

    section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
  5. The firm must keep its listing information, including the contact person, current within 30 days of any change.

    21 CFR 207.33(c)

What FDA wants

FDA asks the firm to write within 15 working days describing each step taken to fix the violations and prevent recurrence, with supporting documents, and to explain any delay and the expected completion date if fixes are not done. The firm may instead send reasoning and evidence if it believes there is no violation.

Who should pay attention

  • firms that submit drug listing data to FDA's eDRLS
  • companies that acquire or rename a firm holding existing NDC listings
  • distributors and pharmacies that rely on National Drug Code Directory data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk